MedPath

CERUS CORPORATION

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

19

Active:2
Completed:9

Trial Phases

4 Phases

Phase 1:2
Phase 2:6
Phase 3:5
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (15 trials with phase data)β€’ Click on a phase to view related trials

Phase 2
6 (40.0%)
Phase 3
5 (33.3%)
Not Applicable
2 (13.3%)
Phase 1
2 (13.3%)

Comparative Effectiveness of INTERCEPT Fibrinogen Complex (IFC) and Cryoprecipitate-AHF (Cryo-AHF) for Treatment of Trauma Associated Hemorrhage

Not yet recruiting
Conditions
Hypofibrinogenemia
Hemorrhage
Interventions
Biological: Pathogen Reduced Cryoprecipitated Fibrinogen Complex
Biological: Cryoprecipitated-Antihemophilic Factor
First Posted Date
2025-10-20
Last Posted Date
2025-10-20
Lead Sponsor
Cerus Corporation
Target Recruit Count
320
Registration Number
NCT07218185
Locations
πŸ‡ΊπŸ‡Έ

University of Colorado, Anschutz Medical Center, Aurora, Colorado, United States

πŸ‡ΊπŸ‡Έ

Jackson Memorial Hospital, University of Miami, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

University of Maryland School of Medicine, Baltimore, Maryland, United States

and more 1 locations

Biotin-Acridine Red Cell Exchange Kinetics

Not Applicable
Not yet recruiting
Conditions
Sickle Cell Disease
First Posted Date
2025-09-04
Last Posted Date
2025-09-10
Lead Sponsor
Cerus Corporation
Target Recruit Count
5
Registration Number
NCT07155031

Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs

Not Applicable
Not yet recruiting
Conditions
Transfusion Reaction, Hemolytic
First Posted Date
2025-09-03
Last Posted Date
2025-09-03
Lead Sponsor
Cerus Corporation
Target Recruit Count
10
Registration Number
NCT07152379

A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1

Phase 2
Recruiting
Conditions
Healthy Subjects
First Posted Date
2025-06-11
Last Posted Date
2025-10-15
Lead Sponsor
Cerus Corporation
Target Recruit Count
70
Registration Number
NCT07015437
Locations
πŸ‡ΊπŸ‡Έ

Hoxworth Blood Center, Cincinnati, Ohio, United States

πŸ‡ΊπŸ‡Έ

American Red Cross Research Laboratory, Norfolk, Virginia, United States

A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated with the INTERCEPT Blood System for Platelets with LED Illuminator.

Phase 2
Not yet recruiting
Conditions
Healthy Subjects
First Posted Date
2024-11-20
Last Posted Date
2025-01-13
Lead Sponsor
Cerus Corporation
Target Recruit Count
60
Registration Number
NCT06697223
Locations
πŸ‡ΊπŸ‡Έ

American Red Cross Research Laboratory, Norfolk, Virginia, United States

πŸ‡ΊπŸ‡Έ

Bloodworks Northwest Research Institute, Seattle, Washington, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

Cerus Corporation Secures $7.2M DoD Contract Amendment to Advance Trauma Hemorrhage Treatment

Cerus Corporation received an additional $7.2 million contract amendment from the U.S. Department of Defense to develop lyophilized INTERCEPT Fibrinogen Complex for treating trauma-related bleeding.

Cerus Corporation Reports Positive Phase 3 Results for INTERCEPT Blood System at ISBT Congress

Cerus Corporation will present positive Phase 3 ReCePI study results for its INTERCEPT Blood System red blood cell treatment at the 35th ISBT Congress in Milan.

Cerus Secures CE Mark for Next-Gen INTERCEPT Blood Pathogen Inactivation System

Cerus Corporation has received CE mark approval for its INT200, a next-generation LED-based illumination device for the INTERCEPT Blood System, enabling commercialization throughout the European Union.

Cerus Highlights INTERCEPT Blood System Advancements at AABB 2024

Cerus Corporation presented data at the AABB Annual Meeting showcasing the benefits of INTERCEPT-treated blood products.

Pathogen-Reduced Cryoprecipitate Trial Aims to Improve Transfusion Outcomes in Cardiac Surgery

A prospective, cluster-randomized trial is underway to compare pathogen-reduced cryoprecipitate (IFC) with conventional cryoprecipitated AHF in cardiac surgery patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.